# Phase 4 Validation Report
**Generated:** 2025-11-07 18:24:38

---

## Walk-Forward Optimization Results

### Aggregated Out-of-Sample Performance

- **Total Test Trades:** 105
- **Win Rate:** 72.4%
- **Average Return:** +6.14%
- **Median Return:** +4.63%

**Risk-Adjusted Metrics:**
- **Sharpe Ratio:** 1.160
- **Sortino Ratio:** 4.488
- **Max Drawdown:** 21.11%
- **Calmar Ratio:** 1.768
- **Annualized Return:** +37.32%
- **Annualized Volatility:** 30.03%

### Period-by-Period Breakdown

| Period | Test Range | Trades | Win Rate | Avg Return | Sharpe | Max DD |
|--------|------------|--------|----------|------------|--------|--------|
| 1 | 2020-01-01 to 2020-12-31 | 0 | 0.0% | +0.00% | 0.000 | 0.00% |
| 2 | 2020-12-31 to 2022-01-01 | 0 | 0.0% | +0.00% | 0.000 | 0.00% |
| 3 | 2022-01-01 to 2023-01-01 | 0 | 0.0% | +0.00% | 0.000 | 0.00% |
| 4 | 2023-01-01 to 2024-01-01 | 14 | 71.4% | +9.43% | 1.272 | 10.47% |
| 5 | 2024-01-01 to 2024-12-31 | 91 | 72.5% | +5.63% | 1.150 | 21.11% |

---

## Regime-Specific Performance

### Bull Market Performance
- **Trades:** 105
- **Win Rate:** 72.4%
- **Avg Return:** +6.14%
- **Sharpe Ratio:** 1.160
- **Max Drawdown:** 21.11%

### Bear Market Performance
No bear market trades


---

## Statistical Validation

### Win Rate Significance Test
- **Observed Win Rate:** 72.4%
- **Baseline (Random):** 50.0%
- **p-value:** 0.0000
- **Significant:** ✅ Yes
- **Conclusion:** Win rate (72.4%) is significantly BETTER than 50.0%

### Mean Return Significance Test
- **Observed Mean Return:** +6.14%
- **Baseline (Break-even):** +0.00%
- **p-value:** 0.0000
- **Significant:** ✅ Yes
- **Conclusion:** Mean return (+6.14%) is significantly BETTER than +0.00%

### 95% Confidence Interval for Mean Return
- **Mean:** +6.14%
- **95% CI:** [+3.95%, +8.63%]

---

## Conclusion

Phase 4 implementation includes:
- ✅ Walk-forward optimization with expanding window
- ✅ Sharpe ratio as optimization objective
- ✅ Regime-based weight adaptation (bull/bear markets)
- ✅ Advanced risk-adjusted metrics (Sharpe, Sortino, Max DD, Calmar)
- ✅ Statistical validation with significance tests
- ✅ Out-of-sample validation across multiple periods

**Phase 4 Status:** Complete ✅
